Compare Amylx Pharmaceuticals Inc (AMLX) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs QUALCOMM, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while QUALCOMM, Inc. trades at $185.19 (market cap $199.37B). The key difference: QUALCOMM, Inc. is far larger — about 100.7× Amylx Pharmaceuticals Inc's market cap, and QUALCOMM, Inc. pays a 1.95% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | QCOM | |
|---|---|---|
Market Cap | $1.98B | $199.37B |
Sector | Health | Technology |
52-Week High | $18.70 | $251.10 |
52-Week Low | $7.64 | $124.07 |
Enterprise Value | $1.70B | $204.85B |
Dividend Yield | — | 1.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Qualcomm (QCOM) trades at $189.16, down 1.01% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported revenue of $44.28 billion in 2025, with a net income margin of 22.31% and robust cash flow from operations of $14.01 billion. Recent news highlights its push into AI and data centers, though competition from Nvidia in the PC chip market poses challenges.
The outlook for QCOM is positive, driven by diversification into automotive and AI, with a consensus price target of $221.21 implying 17% upside. Risks include smartphone market softness and margin pressures, but strong analyst buy ratings (42.65%) and institutional support suggest confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
